GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (FRA:DPOA) » Definitions » COGS-to-Revenue

Assertio Holdings (FRA:DPOA) COGS-to-Revenue : 0.34 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Assertio Holdings COGS-to-Revenue?

Assertio Holdings's Cost of Goods Sold for the three months ended in Mar. 2024 was €10.3 Mil. Its Revenue for the three months ended in Mar. 2024 was €29.9 Mil.

Assertio Holdings's COGS to Revenue for the three months ended in Mar. 2024 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Assertio Holdings's Gross Margin % for the three months ended in Mar. 2024 was 65.55%.


Assertio Holdings COGS-to-Revenue Historical Data

The historical data trend for Assertio Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings COGS-to-Revenue Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.19 0.14 0.12 0.18

Assertio Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.12 0.20 0.29 0.34

Assertio Holdings COGS-to-Revenue Calculation

Assertio Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=24.777 / 139.447
=0.18

Assertio Holdings's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=10.283 / 29.852
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assertio Holdings  (FRA:DPOA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Assertio Holdings's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 10.283 / 29.852
=65.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Assertio Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings (FRA:DPOA) Business Description

Traded in Other Exchanges
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Assertio Holdings (FRA:DPOA) Headlines

No Headlines